West Pharmaceutical Services, Inc. (WST)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.39% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
- Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
- BDX Expands U.S. Manufacturing With $19B Healthcare Investment
- Reasons to Hold HealthEquity Stock in Your Portfolio for Now
- Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
- Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for West Pharmaceutical Services, Inc..
Full WST Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.